Results 191 to 200 of about 8,170,338 (315)

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Microscopic basis of reaction center modulation in PsbA variants of photosystem II. [PDF]

open access: yesProc Natl Acad Sci U S A
Bhattacharjee S   +3 more
europepmc   +1 more source

100 Glimpses : Tom Day

open access: yes
100 Glimpses is a series of short documentaries produced by the Sight Center of Northwest Ohio. The series explores the organization's history. The Sight Center was founded in 1923 as the Toledo Society for the Blind.
Sight Center of Northwest Ohio (Toledo, Ohio)
core  

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Barrierless Electron Transfer in a Photosynthetic Reaction Center Model. [PDF]

open access: yesAngew Chem Int Ed Engl
Ullrich T   +3 more
europepmc   +1 more source

100 Glimpses : The Labino

open access: yes
100 Glimpses is a series of short documentaries produced by the Sight Center of Northwest Ohio. The series explores the organization's history. The Sight Center was founded in 1923 as the Toledo Society for the Blind.
Sight Center of Northwest Ohio (Toledo, Ohio)
core  

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

open access: yesMolecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy